VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate
Read more
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in
Read more
Clinical outcome improvement (based on ordinal scale) with leronlimab at day 14 was 400% better than placebo arm with p-value
Read more
CD12 trial results also indicated that five out of six patients on ECMO recovered VANCOUVER, Washington, March 29, 2021 (GLOBE
Read more
VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
CytoDyn expects to release CD12 data and complete discussions with various regulatory agencies within 2 to 3 weeks VANCOUVER, Washington,
Read more
Manuscript entitled: “Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with
Read more
VANCOUVER, Washington, Dec. 29, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
The agency will also consider eINDs for patients in other hospitals who qualify for inclusion criteria similar to CD12 The
Read more
Rapid Enrollment Expected, As Many People Have Already Volunteered VANCOUVER, Washington, Nov. 17, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the
Read more